Sanofi re­sponds to patent spat with Am­gen as Supreme Court ar­gu­ments set for March

The newest step in the saga be­tween Am­gen and Sanofi’s patent tug-of-war is in Sanofi’s court, just a mat­ter of weeks be­fore oral ar­gu­ments.

Just over a month af­ter Am­gen filed a re­sponse to the Supreme Court against Sanofi, the French phar­ma is coun­ter­ing Am­gen’s claims that the Fed­er­al Cir­cuit’s pre­vi­ous stan­dard harms in­no­va­tion.

Sanofi said in its fil­ing Fri­day that Am­gen ob­tained ad­di­tion­al patents to try and broad­ly claim the en­tire genus of PC­SK9-block­ing an­ti­bod­ies af­ter Sanofi and Re­gen­eron had al­ready de­vel­oped Pralu­ent. On top of that, Sanofi claims that Am­gen’s ra­tio­nale that a Fed­er­al Cir­cuit stan­dard harms in­no­va­tion is not en­tire­ly true.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.